Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus plantarum HUN082
- Development stage
- Unknown
- Lead developer
- Hainan University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus plantarum HUN082 (also known as Lactiplantibacillus plantarum HNU082 or Lp082) is a specific probiotic bacterial strain within the species L. plantarum. This strain has been studied for its ability to colonize and adapt to the gut environment across multiple host species (human, mouse, zebrafish), where it acquires mutations that enhance carbohydrate utilization and acid tolerance[3]. In preclinical models of colitis in mice, supplementation with Lp082 demonstrated therapeutic effects by protecting the intestinal mucosal barrier, modulating inflammatory pathways (including reducing neutrophil infiltration), and actively regulating the gut microbiome composition[6]. The probiotic’s mechanisms include competitive inhibition of pathogenic bacteria adhesion and modulation of host immune responses. No evidence was found for approval or clinical use in humans; current data are primarily from animal studies.
- Other names
- Lactiplantibacillus plantarum HNU082Lp082Lp-082Lp 082
Beyond the preview
Go deeper on lactobacillus plantarum HUN082.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus plantarum HUN082.